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Background
in children with severe persistent uncontrolled asthma
atopic dermatitis (AD) is often characterized by persis-
tent continually relapsing.
According to the approach ICON for children > 6 y o
with severe uncontrolled asthma as an additional treat-
ment from 3-4 step of therapy omalizumab (Omab) is
recommended for use of. We report on the experience
of the use of Omab in children with asthma and AD.
Methods
Medical files of 64 children treated with Omab were
analysed: 36% of patients have had a concomitant diag-
nosis of AD, 39.1% of them suffered of severe AD
(SCORAD >60-70) at baseline.
All of the following data were recorded, at baseline
and after 6, 12 and 24 mo of Omab therapy: values of
SCORAD, duration of periods of remission and periods
of exacerbation of AD, quality of life (on a scale CDLQI
and ACQ), requirement to use of topical steroids and
maintenance asthma therapy, PFTs values, symptom
scores and control level (GINA, ACT).
Results
The characteristics of children with uncontrolled severe
asthma and persistent AD were: mean age of the begin-
ning of Omab therapy – 11.8 y, 60% girls, mean SCORAD
index 72 points, quality of life (questionnaire CDLQI –
mean 15,2), the requirement of topical steroids was high
(mean 6.2 g/day of therapy), the duration of periods of
remission were extremely short and periods of
exacerbation of AD were more than 280 days/y. Initial
maintenance asthma therapy was ICS (mean daily dose:
750µg fluticasone) with LABA, asthma symptom control
questionnaires (mean ACT: 7.5, mean ACQ 23), mean
FEV1 76%, mean PFT 69.7%.
After prolonged Omab therapy following indices signifi-
cantly improved: mean SCORAD 28, 17 and 10 points
(after 6, 12 and 24 mo accordingly), mean CDLQI 9, 4,
and 2.1; the use of topical steroids 2.9, 1.6 and 0.7 g/d,
periods of AD remission were extended, asthma control
(mean ACT: 19, mean ACQ 12), mean FEV1 96%.
The effectiveness of treatment was directly correlated
with the duration of therapy.
Conclusions
Omab therapy not only improves asthma control, it
allows to reduce of the manifestations and rate of exacer-
bations of severe AD and has shown steroid saving effect.
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